Patents by Inventor Lars Wahlberg
Lars Wahlberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8501467Abstract: Cultures of cells immunoreactive for glial fibrillary acidic protein (GFAP), as well as for the intermediate filament marker nestin were grown in a medium including epidermal growth factor (EGF) and serum. The cultured cells had the morphology of astroglial cells. The cells can be proliferated in adherent or suspension cultures. Depending on the culture conditions, the cells can be induced to differentiate to neurons or glial cells. The cultures can be expanded over a large number of passages during several months, and survive, express an astroglial phenotype and integrate well after transplantation into both neonatal and adult rat forebrain.Type: GrantFiled: December 23, 2009Date of Patent: August 6, 2013Assignee: StemCells California, Inc.Inventors: Lars Wahlberg, Kenneth Campbell, Charlotta Skogh, Cecilia Eriksson, Klas Wictorin
-
Publication number: 20110003358Abstract: Cultures of cells immunoreactive for glial fibrillary acidic protein (GFAP), as well as for the intermediate filament marker nestin were grown in a medium including epidermal growth factor (EGF) and serum. The cultured cells had the morphology of astroglial cells. The cells can be proliferated in adherent or suspension cultures. Depending on the culture conditions, the cells can be induced to differentiate to neurons or glial cells. The cultures can be expanded over a large number of passages during several months, and survive, express an astroglial phenotype and integrate well after transplantation into both neonatal and adult rat forebrain.Type: ApplicationFiled: December 23, 2009Publication date: January 6, 2011Applicant: NsGene A/SInventors: Lars Wahlberg, Kenneth Campbell, Charlotta Skogh, Cecilia Ericksson, Klas Wictorin
-
Patent number: 7651853Abstract: Cultures of cells immunoreactive for glial fibrillary acidic protein (GFAP), as well as for the intermediate filament marker nestin were grown in a medium including epidermal growth factor (EGF) and serum. The cultured cells had the morphology of astroglial cells. The cells can be proliferated in adherent or suspension cultures. Depending on the culture conditions, the cells can be induced to differentiate to neurons or glial cells. The cultures can be expanded over a large number of passages during several months, and survive, express an astroglial phenotype and integrate well after transplantation into both neonatal and adult rat forebrain.Type: GrantFiled: October 31, 2007Date of Patent: January 26, 2010Assignee: NsGene A/SInventors: Lars Wahlberg, Kenneth Campbell, Charlotta Skogh, Cecilia Eriksson, Klas Wictorin
-
Publication number: 20090099952Abstract: An exchange system and a method for trading orders on an exchange market and a related broker workstation. One or more user defined order matrixes allows a user to design a trading strategy by manually, or by means of algorithms using current and/or historical market data, determine trading parameters such as part order size, price level, time delay between consecutive part orders. An order having a total volume and at least one such order matrix associated therewith is received from a market participant. The order matrix specifies predetermined portions of the order's total volume. A first portion of the order's total volume is determined in accordance with the order matrix and information is sent to display the that portion to the market. A next portion of the order's total volume is generated in accordance with the order matrix and information is then sent to display that portion to the market.Type: ApplicationFiled: October 12, 2007Publication date: April 16, 2009Inventor: Lars Wahlberg
-
Publication number: 20080286323Abstract: The present invention relates to human cell lines genetically modified to overexpress bioactive NGF. In another aspect the present invention relates to encapsulated human cell lines genetically modified to overexpress bioactive NGF, which can be used in therapy of Alzheimer's disease, peripheral neuropathy and other neurological disorders amenable to local and prolonged NGF therapy.Type: ApplicationFiled: January 18, 2005Publication date: November 20, 2008Applicant: NSGENE A/SInventors: Jens Tornoe, Phillip Kusk, Lars Wahlberg
-
Publication number: 20080138895Abstract: Cultures of cells immunoreactive for glial fibrillary acidic protein (GFAP), as well as for the intermediate filament marker nestin were grown in a medium including epidermal growth factor (EGF) and serum. The cultured cells had the morphology of astroglial cells. The cells can be proliferated in adherent or suspension cultures. Depending on the culture conditions, the cells can be induced to differentiate to neurons or glial cells. The cultures can be expanded over a large number of passages during several months, and survive, express an astroglial phenotype and integrate well after transplantation into both neonatal and adult rat forebrain.Type: ApplicationFiled: October 31, 2007Publication date: June 12, 2008Inventors: Lars Wahlberg, Kenneth Campbell, Charlotta Skogh, Cecilia Eriksson, Klas Wictorin
-
Patent number: 7303912Abstract: Cultures of cells immunoreactive for glial fibrillary acidic protein (GFAP), as well as for the intermediate filament marker nestin were grown in a medium including epidermal growth factor (EGF) and serum. The cultured cells had the morphology of astroglial cells. The cells can be proliferated in adherent or suspension cultures. Depending on the culture conditions, the cells can be induced to differentiate to neurons or glial cells. The cultures can be expanded over a large number of passages during several months, and survive, express an astroglial phenotype and integrate well after transplantation into both neonatal and adult rat forebrain.Type: GrantFiled: February 22, 2005Date of Patent: December 4, 2007Assignee: NsGene A/SInventors: Lars Wahlberg, Kenneth Campbell, Charlotta Skogh, Cecilia Eriksson, Klas Wictorin
-
Publication number: 20070275026Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells. More specifically the invention relates to therapy based on the biological function of a secreted therapeutic protein. NsG33, in particular for the treatment of disorders of the nervous system. NsG33 is a nerve survival and growth factor with antiapoptotic effects on a cell line with neuronal potential and with neuroprotective and/or neurogenesis effects on a neural precursor cell line and on primary striatal cultures. The invention also relates to novel bioactive NsG33 polypeptide fragments and the corresponding encoding DNA sequences.Type: ApplicationFiled: March 30, 2005Publication date: November 29, 2007Applicant: NSGENE A/SInventors: Mette Gronborg, Philip Kusk, Nikolaj Blom, Thomas Petersen, Teit Johansen, Soren Brunak, Lars Wahlberg
-
Publication number: 20070128168Abstract: A human embryonal stem cell, neural stem cell, neural precursor cell, neural cell or dopaminergic neuron is genetically modified to overexpress at least one of certain genes identified as regulated in the developing human ventral mesencephalon, and more particularly, up-regulated in the ventral tegmentum. The genes are associated with dopaminergic differentiation.Type: ApplicationFiled: November 15, 2006Publication date: June 7, 2007Applicant: NsGene A/SInventors: Jesper Jorgensen, Lars Wahlberg
-
Publication number: 20060239966Abstract: The present invention concerns methods and compositions for gene therapy, in particular in vivo gene therapy for delivery of bioactive Neurturin for the treatment of Parkinson's Disease. In another aspect the invention relates to virus expression constructs comprising a mammalian signal peptide linked to a mature or N-terminally truncated Neurturin without a functional pro-region between the signal peptide and the Neurturin. These viral expression constructs are required for efficient secretion of bioactive Neurturin in in vivo gene therapy. The invention also concerns mammalian cells capable of producing Neurturin in increased amounts as well as the use of these cells for recombinant production of bioactive Neurturin and for therapeutic use.Type: ApplicationFiled: October 20, 2004Publication date: October 26, 2006Inventors: Jens Tornøe, Carl Rosenblad, Lars Wahlberg
-
Publication number: 20050191745Abstract: Cultures of cells immunoreactive for glial fibrillary acidic protein (GFAP), as well as for the intermediate filament marker nestin were grown in a medium including epidermal growth factor (EGF) and serum. The cultured cells had the morphology of astroglial cells. The cells can be proliferated in adherent or suspension cultures. Depending on the culture conditions, the cells can be induced to differentiate to neurons or glial cells. The cultures can be expanded over a large number of passages during several months, and survive, express an astroglial phenotype and integrate well after transplantation into both neonatal and adult rat forebrain.Type: ApplicationFiled: February 22, 2005Publication date: September 1, 2005Inventors: Lars Wahlberg, Kenneth Campbell, Charlotta Skogh, Cecilia Eriksson, Klas Wictorin
-
Publication number: 20050089960Abstract: The present invention concerns improved methods and compositions for producing a Neublastin polypeptide as well as local delivery of Neublastin to specific regions of the nervous system including the central nervous system and the eye for example by gene therapy. The invention also concerns Neublastin expression constructs which do not encode a pro-region of a Neublastin polypeptide, which expression construct result in increased secretion of bioactive Neublastin. The invention includes the delivery of Neublastin from transduced or transfected cells encapsulated into a macrocapsule with a semipermeable membrane. The invention further concerns mammalian cells capable of producing Neublastin in increased amounts.Type: ApplicationFiled: June 10, 2004Publication date: April 28, 2005Applicant: NSGENE A/SInventors: Lars Wahlberg, Mette Gronborg, Philip Kusk, Jens Tornoe
-
Patent number: 6878543Abstract: Cultures of cells immunoreactive for glial fibrillary acidic protein (GFAP), as well as for the intermediate filament marker nestin were grown in a medium including epidermal growth factor (EGF) and serum. The cultured cells had the morphology of astroglial cells. The cells can be proliferated in adherent or suspension cultures. Depending on the culture conditions, the cells can be induced to differentiate to neurons or glial cells. The cultures can be expanded over a large number of passages during several months, and survive, express an astroglial phenotype and integrate well after transplantation into both neonatal and adult rat forebrain.Type: GrantFiled: October 24, 2000Date of Patent: April 12, 2005Assignee: NsGene SAInventors: Lars Wahlberg, Kenneth Campbell, Charlotta Skogh, Cecilia Eriksson, Klas Wictorin
-
Publication number: 20040247571Abstract: The invention provides a means for efficiently generating large numbers of TH expressing neural cells for neurotransplantation into a host to treat neurodegenerative disease, neurological trauma, stroke, or in other neurodegenerative disease, neurological trauma, stroke, or in other diseases of the nervous system involving loss of neural cells, particularly Parkinson's disease.Type: ApplicationFiled: May 26, 2004Publication date: December 9, 2004Inventors: Xia Meijer, Mette Gronborg, Lars Wahlberg
-
Patent number: 5643773Abstract: Elongated seamless capsules containing biological material are prepared by a method in which a coagulant, which includes a cell suspension or other biological material, and a polymeric casting solution are extruded through a common extrusion port having at least two concentric bores, such that the coagulant is extruded through an inner bore and the polymeric casting solution is extruded through an outer bore. Extrusion of the coagulant is initiated subsequent to initiating delivery of the casting solution to form a capsule having a curved and smooth leading edge shape. Delivery of the coagulant is then shut off, and extrusion of the casting solution is terminated either immediately or after some predetermined time. This procedure can be modified to form in the capsule a coaxial rod that is connected to one end but not the other end of the capsule.Type: GrantFiled: April 27, 1995Date of Patent: July 1, 1997Assignee: Brown University Research FoundationInventors: Patrick Aebischer, John F. Mills, Lars Wahlberg, Edward J. Doherty, Patrick A. Tresco
-
Patent number: 5418154Abstract: Elongated seamless capsules containing biological material are prepared by a method in which a coagulant, which includes a cell suspension or other biologically active factor, and a polymeric casting solution are extruded through a common extrusion port having at least two concentric bores, such that the coagulant is extruded through the inner bore and the polymeric casting solution is extruded through the outer bore. The method involves initiating extrusion of the coagulant subsequent to initiating delivery of the casting solution through the respective bores to form a capsule having a curved and smooth leading edge shape. Delivery of the coagulant is then shut off, and extrusion of the casting solution is terminated either immediately or after some predetermined time.Type: GrantFiled: December 24, 1992Date of Patent: May 23, 1995Assignee: Brown University Research FoundationInventors: Patrick Aebischer, John F. Mills, Lars Wahlberg, Edward J. Doherty, Patrick A. Tresco
-
Patent number: 5389535Abstract: Methods and systems are disclosed for encapsulating viable cells which produce biologically-active factors. The cells are encapsulated within a semipermeable, polymeric membrane by co-extruding an aqueous cell suspension and a polymeric solution through a common port to form a tubular extrudate having a polymeric outer coating which encapsulates the cell suspension. For example, the cell suspension and the polymeric solution can be extruded through a common extrusion port having at least two concentric bores, such that the cell suspension is extruded through the inner bore and the polymeric solution is extruded through the outer bore. The polymeric solution coagulates to form an outer coating. As the outer coating is formed, the ends of the tubular extrudate can be sealed to form a cell capsule. In one embodiment, the tubular extrudate is sealed at intervals to define separate cell compartments connected by polymeric links.Type: GrantFiled: December 17, 1993Date of Patent: February 14, 1995Assignee: Brown University Research FoundationInventors: Patrick Aebischer, Lars Wahlberg
-
Patent number: 5284761Abstract: Methods and systems are disclosed for encapsulating viable cells which produce biologically-active factors. The cells are encapsulated within a semipermeable, polymeric membrane by co-extruding an aqueous cell suspension and a polymeric solution through a common port to form a tubular extrudate having a polymeric outer coating which encapsulates the cell suspension. For example, the cell suspension and the polymeric solution can be extruded through a common extrusion port having at least two concentric bores, such that the cell suspension is extruded through the inner bore and the polymeric solution is extruded through the outer bore. The polymeric solution coagulates to form an outer coating. As the outer coating is formed, the ends of the tubular extrudate can be sealed to form a cell capsule. In one embodiment, the tubular extrudate is sealed at intervals to define separate cell compartments connected by polymeric links.Type: GrantFiled: February 26, 1992Date of Patent: February 8, 1994Assignee: Brown University Research FoundationInventors: Patrick Aebischer, Lars Wahlberg
-
Patent number: 5283187Abstract: Living cells such as animal cells which produce biologically active factors are encapsulated within a semipermeable, polymeric membrane such as polyacrylate by co-extruding an aqueous cell suspension and a polymeric solution through a common port having at least one concentric bores to form a tubular extrudate having a polymeric membrane which encapsulates the cell suspension. The cell suspension is extruded through an inner bore and the polymeric solution is extruded through an outer bore while a pressure differential is maintained between the cell suspension and the polymeric solution to impede solvent diffusion from the polymeric solution into the cell suspension. The polymeric solution coagulates to form an outer coating or membrane as the polymeric solution and the cell suspension are extruded through the extrusion port. As the outer membrane is formed, the ends of the tubular extrudate are sealed to form a cell capsule.Type: GrantFiled: January 8, 1991Date of Patent: February 1, 1994Assignee: Brown University Research FoundationInventors: Patrick Aebischer, Lars Wahlberg
-
Patent number: 5158881Abstract: Methods and systems are disclosed for encapsulating viable cells which produce biologically-active factors. The cells are encapsulated within a semipermeable, polymeric membrane by co-extruding an aqueous cell suspension and a polymeric solution through a common port to form a tubular extrudate having a polymeric outer coating which encapsulates the cell suspension. For example, the cell suspension and the polymeric solution can be extruded through a common extrusion port having at least two concentric bores, such that the cell suspension is extruded through the inner bore and the polymeric solution is extruded through the outer bore. The polymeric solution coagulates to form an outer coating. As the outer coating is formed, the ends of the tubular extrudate can be sealed to form a cell capsule. In one embodiment, the tubular extrudate is sealed at intervals to define separate cell compartments connected by polymeric links.Type: GrantFiled: January 8, 1990Date of Patent: October 27, 1992Assignee: Brown University Research FoundationInventors: Patrick Aebischer, Lars Wahlberg